Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Inovio Pharmaceuticals Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.71 (market cap $4.59B), while Inovio Pharmaceuticals Inc trades at $1.09 (market cap $112.19M). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 40.9× Inovio Pharmaceuticals Inc's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DFTX | INO | |
|---|---|---|
Market Cap | $4.59B | $112.19M |
Volume | 2,103,937 | 3,201,278 |
Sector | Health | Health |
52-Week High | $48.45 | $2.65 |
52-Week Low | $10.68 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $3.55B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
